Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty
2023-06-05 19:12
Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
2023-06-02 00:06
Sirnaomics to receive HK$8 million subsidy from the HKSTP Clinical Translational Catalyst Plan
2023-05-17 21:13
RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV-1730 COVID-19 Booster Vaccine
2023-04-28 00:29
Sirnaomics Launches Phase I Clinical Trial for GalNAc Factor XI Program
2023-04-12 16:25
Sirnaomics Announces 2022 Annual Results
2023-03-28 19:26
Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform at the 4th Annual RNAi-Based Therapeutics Summit
2023-03-20 23:27
RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting
2023-02-07 16:34
Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers
2023-02-01 15:00
Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors
2022-12-21 00:39
Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ
2022-12-14 23:47
Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
2022-12-14 01:41
Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
2022-12-14 01:40
Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment
2022-11-08 05:13
Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences
2022-10-19 14:55
Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference
2022-09-20 22:40
Sirnaomics to Present at 3rd Annual Jefferies Asia Forum
2022-09-07 11:32
Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
2022-08-29 15:59
Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases
2022-08-26 21:54
Sirnaomics Becoming A Constituent of Hang Seng Family of Indexes
2022-08-22 08:33
1
2
3